Impact of genetic targets on cancer therapy: Hepatocellular cancer

Advances in Experimental Medicine and Biology

Volumn 779, Issue , 2013, Pages 67-90

  Hamed, Osama ^a   Kimchi, Eric T ^a   Sehmbey, Mandeep ^a   Gusani, Niraj J ^a   Kaifi, Jussuf T ^a   Staveley O'carroll, Kevin ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Hepatocellular carcinoma; Monoclonal antibodies; Sorafenib; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

AEG 35156; AMSILAROTENE; AVE 1642; BELINOSTAT; BEVACIZUMAB; BORTEZOMIB; BRIVANIB; CETUXIMAB; CIXUTUMUMAB; ERLOTINIB; GEMCITABINE; IMATINIB; LAPATINIB; LINIFANIB; LINSITINIB; MONOCLONAL ANTIBODY; OXALIPLATIN; PANOBINOSTAT; PI 88; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RESMINOSTAT; SELUMETINIB; SORAFENIB; SUNITINIB; TIVANTINIB; TREBANANIB; UNINDEXED DRUG; VORINOSTAT;

ALOPECIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ASTHENIA; CANCER GENETICS; CANCER GROWTH; CANCER THERAPY; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG FATALITY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOMODULATION; INJECTION SITE BLEEDING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER RESECTION; LIVER TUMOR; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUSCLE SPASM; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR ABLATION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84873591640     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-6176-0_4     Document Type: Review

References (113)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. El-Serag HB. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology. 2004;127:S27-34.
3. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 2004;127:S35-50.
4. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005-14.
5. Bugianesi E. Non-Alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11(1):191-207.
6. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
7. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855-9.
8. Sherman M, Bruix J. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020-2.
9. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132-41.
10. El Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population- Based study. J Hepatol. 2006;44:158-66.
11. Thomas MB, Zhu AX. Hepatocellular carcinoma: The need for progress. J Clin Oncol. 2005;23(13):2892-9.
12. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A metaanalysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51(4):1274-83.
13. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(SUPPL8):S4-66.
14. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983-93.
15. International Consensus Group for Hepatocellular Neoplasia. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658-64.
16. Fernandez M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol. 2009;50:604-20.
17. Kaposi-Novak P, Libbrecht L, Woo HG, et al. Central role of c- Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 2009;69:2775-82.
18. Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis. 2010;42(SUPPL3):S235-41.
19. Woo HG, Park ES, Thorgeirsson S, Kim YJ. Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog. 2011;50(4):235-43. doi: Doi: 10.1002/mc.20691 .
20. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003;361:923-9.
21. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40:667-76.
22. Wang SM, Ooi LL, Hui KM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res. 2007;13:6275-83.
23. Woo HG, Park ES, Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14:2056-64.
24. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression infixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004.
25. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One. 2010;5:e9749.
26. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008;47:897-907
27. Gehrau R, Mas V, Archer KJ, Maluf D. Molecular classification and clonal differentiation of hepatocellular carcinoma: The step forward for patient selection for liver transplantation. Exp Rev Gastroenterol Hepatol. 2011;5(4):539-52.
28. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99-111.
29. Okamoto M, Utsunomiya T, Wakiyama S, et al. Specific geneexpression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol. 2006;13:947-54.
30. Villanueva A, Minguez B, Forner A, et al. Hepatocellular carcinoma: Novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317-28.
31. Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence in hepatocellular carcinoma. Gastroenterology. 2011;140(5):1501-12.
32. Ura S, Honda M, Yamashita T, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009;49:1098-112.
33. Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45:938-47.
34. Nam SW, Park JY, Ramasamy A, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology. 2005;42:809-18.
35. Katoh H, Ojima H, Kokubu A, et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: Putative therapeutic targets. Gastroenterology. 2007;133:1475-86.
36. Van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of geneexpression patterns. Nature. 2008;452:564-70.
37. Hoshida Y, Toffanin S, Lachenmayer A, et al. Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements. Semin Liver Dis. 2010;30:35-51.
38. Tovar V, Alsinet C, Villanueva A, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 2010;52:550-9.
39. Villanueva A, Chiang DY, Newell P. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-83. 1983 e1-11.
40. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140(5):1410-26. Epub 2011 Mar 13.
41. Lee JS, Chu IS, Mikaelyan A, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004;36:1306-11.
42. Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-94.
43. Hayashi PH, Di Bisceglie AM. The progression of hepatitis B- And C-infections to chronic liver disease and hepatocellular carcinoma: Epidemiology and pathogenesis. Med Clin North Am. 2005;89(2):371-8.
44. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64(1):51-68.
45. Yuen MF, Wu PC, Lai VC, Lau JY, Lai CL. Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer. 2001;911:106-12.
46. Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C, Levrero M. The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc Natl Acad Sci USA. 1997;94:8162-7.
47. Tellinghuisen R. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol. 2002;5(4):419-27.
48. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Purcell RH, Alter HJ. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671-5.
49. Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in s cell lines expressing the Hepatitis C Virus HCV core protein. Oncogene. 2001;20:2606-10.
50. Marra M, Sordelli IM, Lombardi A, Lamberti M. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview. J Transl Med. 2011;9:171.
51. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
52. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
53. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group, Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28(10):1772.
54. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
55. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
56. www.clinicaltrials.gov .
57. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711.
58. Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: Should treatment be expanded? Dig Liver Dis. 2010;42(SUPPL3):S258-63.
59. Peck-Radosavljevic M, Greten TF, Lammer J, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22(4):391-8.
60. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-300.
61. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced Hepatocellular cancer. J Clin Oncol. 2005;23:6657-63.
62. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110:1059-67.
63. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study. Lancet Oncol. 2009;10(8):794-800.
64. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol. 2009;27(18):3027-35.
65. Toh H, Chen P, Carr BI, et al. A phase II study of ABT-869 in Hepatocellular carcinoma (HCC): Interim analysis. J Clin Oncol. 2009;27:222s. abstr 4581.
66. Gupta N, Chiu Y, Toh HC, et al. Preliminary pharmacokinetics and safety comparison of Child Pugh A vs. Child Pugh B patients enrolled in a phase 2 study of Linifanib (ABT-869) in hepatocellular carcinoma [abstract]. 2010 ESMO Congress, Milan, Italy, Abstract number 3105.
67. Park JW, Finn RS, Kim JS, et al. Phase II, open-label study of brivanib asfirst-line therapy in patients with advanced Hepatocellular carcinoma. Clin Cancer Res. 2011;17:1973-83.
68. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64:777-83.
69. Trujillo JI. MEK inhibitors: A patent review 2008-2010. Expert Opin Ther Pat. 2011; 21(7):1045-69. Epub 2011 May 9.
70. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, et al. Phase II study of the mitogen-Activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011;29(17):2350-6. Epub 2011 Apr 25.
71. You H, Ding W, Dang H, Jiang Y, Rountree CB. c- Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 2011;54(3):879-89. doi: Doi: 10.1002/hep.24450 [Epub ahead of print].
72. A Santoro, M. Simonelli, P. Zucali, L. Rimassa, N. N. Senzer, L. H. Camacho, L. Bolondi, M. Lamar, G. Abbadessa, J. A phase Ib safety trial of ARQ 197 in cirrhotic patients with hepatocellular carcinoma (HCC). 2010 Gastrointestinal Cancers Symposium, Orlando, FL, Abstract 187.
73. T. Yau, C.-J. Yen, P.-J. Chen, Y. Chau, R. Lencioni, H. Kallender, L.H. Ottesen, A phase I/II study of Foretinib, a oral Multikinase Inhibitor targeting MET in advanced Impact of Genetic Targets on Cancer Therapy: Hepatocellular Cancer 89 HCC The International Liver Congress, 2011 ( European Association for the study of the Liver Disease 2011) Berlin, Germany, 30 Mar-3 Apr 2011.
74. Treiber G. mTOR inhibitors for hepatocellular cancer: A forward-moving target. Expert Rev Anticancer Ther. 2009;9(2):247-61.
75. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972-83. 1983.e1-11.
76. Heuer M, Benko T, Cicinnati VR, Kaiser GM, Sotiropoulos GC, Baba HA, et al. Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines. Transplant Proc. 2009;41:359-65.
77. Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-Term outcomes and side effects. Transplantation. 2007;83:1162-8.
78. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, et al. Sirolimusbased immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc. 2008;40:3548-53.
79. Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol. 2008;13:66-70.
80. Huynh H, Chow KP, Soo KC, Toh HC, Choo SP, Foo KF, et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med. 2009;13:1371-80.
81. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med. 2009;13:2673-83.
82. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Apr 27. doi: 10.1002/cncr.26165 . [Epub ahead of print].
83. Reichert JM, Rosensweig CJ, Faden LB, et al. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23:1073-8.
84. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296-313.
85. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-7.
86. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992-8.
87. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898-903.
88. Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer. 2011;117(14):3187-92. doi: Doi: 10.1002/cncr.25889 . Epub 2011 Jan 24.
89. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008;129:245-51.
90. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005;41:307-14.
91. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of Cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(3):581-9.
92. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: Results of a multicenter phase 2 study. Cancer. 2008;112(12):2733-9.
93. Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol. 2006;71:1435-48.
94. Turnbull J, Powell A, Guimond S. Heparan sulfate: Decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 2001;11:75-82.
95. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z. Development of heparanase inhibitors for anticancer therapy. Curr Med Chem. 2006;13:2101-11.
96. McKenzie EA. Heparanase: A target for drug discovery in cancer and in fl ammation. Br J Pharmacol. 2007;151:1-14.
97. Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol. 2009;50(5):958-68. Epub 2009 Feb 15.
98. Spratlin JL, Pitts TM, Kulikowski GN, et al. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 2011;31(4):1093-103.
99. Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med. 2010;10(54):462-70.
100. Chambon P. The retinoid signaling pathway: Molecular and genetic analyses. Semin Cell Biol. 1994;5:115-25.
101. Murakami K, Wierzba K, Sano M, et al. TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. Clin Exp Metastasis. 1998;16:323-31.
102. Shibata J, Murakami K, Wierzba K, et al. Anticancer effect of 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity. Anticancer Res. 2000;20:3169-76.
103. Duckett CS, Li F, Wang Y, Tomaselli KJ, Thompson CB, Armstrong RC. Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and cytochrome c. Mol Cell Biol. 1998;18(1):608-15.
104. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev. 1999;13(3):239-52.
105. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, et al. Safety, pharmacokinetics, andantitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009;27(21):3557-65.
106. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA. 2010;304(19):2154-60.
107. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411-6.
108. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26:3709-14.
109. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res. 2005;11:397-405.
110. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27(6):843-50. Epub 2009 Jan 12.
111. Russo FP, Parola M. Stem and progenitor cells in liver regeneration and repair. Cytotherapy. 2011;13:135-44.
112. Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci. 2011;7(5):517-35.
113. Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62:1212-8.